Afamelanotide is a synthetic 13-amino-acid analogue of alpha-MSH with norleucine at position 4 and D-phenylalanine at position 7, first reported in 1980 as a highly potent, long-acting melanotropin. It was developed clinically as a subcutaneous implant for erythropoietic protoporphyria.
Class
α-MSH analogue (melanocortin-1 receptor agonist)
Type
peptide, 13 residues
Also known as
Melanotan I, MT-1, [Nle4,D-Phe7]-α-MSH, NDP-α-MSH, CUV1647, Scenesse
1980: Sawyer TK, et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. PNAS 77(10):5754–5758.
Regulatory status
Authorised in the EU on 22 December 2014 (Scenesse, under exceptional circumstances) and approved by the FDA in 2019, both for adults with erythropoietic protoporphyria.
SHLabz batch results
No SHLabz batch of Afamelanotide has a published report yet. Each batch is tested by an independent laboratory, and the report for a batch is available on request through the contact page.
This sheet describes a molecule and the published research on it. It is not advice about use, and SHLabz products are not for human or veterinary use.
Trusted research supplier — UAE & GCC
The UAE & GCC’s Trusted Source for Lab‑Verified Research Peptides
Research-grade peptides at ≥99% purity, third-party HPLC tested and
released against a certificate of analysis. 1–2 working days across the UAE, 3–5 across the GCC.
≥99% purity, third-party HPLC tested and
released against a certificate of analysis. Dispatched the same working day.
